Recent Updates
Recently added Catalysts

RVT-1401

Phase 2

Graves' Ophthalmopathy | Small molecule | Endocrine |Immunovant, Inc.|Last Updated: Dec 20, 2023

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment7

FDA Designations

No designations recorded

Clinical trial landscape

RVT-1401 · 2 trials · 2 indications

Phase 2 2
NCT03863080A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsMyasthenia Gravis
COMPLETED17 Analytics
NCT03922321Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)Graves' Ophthalmopathy
COMPLETED7 Analytics
PHASE2COMPLETED
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
Myasthenia GravisUnlock trial analytics
PHASE2COMPLETED
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
Graves' OphthalmopathyUnlock trial analytics

Study Endpoints

Primary Endpoints

Double-Blind Treatment Period: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Up to Week 18

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Open-Label Extension Period: Number of Participants Reporting AEs and SAEs
Up to Week 18

An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs are defined as those AEs that started or worsened in severity after the initiation of study drug administration. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Vital Signs
Up to Week 7

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

Open-label Extension Period: Number of Participants With Clinically Significant Changes in Vital Signs
Up to Week 18

Vital signs including SBP, DBP, pulse rate and temperature were measured after resting for at least 5 minutes in a semi-supine position.

Double-blind Treatment Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Up to Week 7

Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

Open-label Extension Period: Number of Participants With Clinically Significant Changes in Clinical Laboratory Parameters
Up to Week 18

Clinical laboratory parameters included clinical chemistry, hematology and urinalysis.

Double-Blind Treatment Period: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Up to Week 7

Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

Open-label Extension Period: Number of Participants With Clinically Significant Changes in ECG
Up to Week 18

Twelve-lead ECG was performed after 5 minutes of rest in the supine position.

Double-blind Treatment Period: Percent Change From Baseline in Levels of Total Immunoglobulin G (IgG)
Baseline (Day 1) and Up to Week 7

Serum samples were collected for the analysis of total immunoglobulin G. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Double-blind Treatment Period: Percent Change From Baseline in IgG Subclasses 1, 2, 3 and 4
Baseline (Day 1) and Up to Week 7

Serum samples were collected for the analysis of IgG 1, 2, 3 and 4 levels. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Double-Blind Treatment Period: Percent Change From Baseline in Anti-acetylcholine Receptor Immunoglobulin G (Anti-AChR-IgG) at Week 7
Baseline (Day 1) and Week 7

Serum samples were collected for the analysis of Anti-AChR-IgG. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7) minus the Baseline value, divided by the Baseline value x 100.

Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment Period
from Baseline up to Week 6

AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug and on or before the date of the last dose of study drug + 42 days, or had no recorded start date and the stop date was in between the date of the first dose and the last dose of study drug + 42 days. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.

Number of Participants With Clinically Significant Findings Related to Vital Signs
up to Week 18

Clinical significance was determined by the investigator.

Number of Participants With a Change From Normal Physical Examination Findings at Baseline to Abnormal Physical Examination Findings at the End of the Study
up to Week 18

Abnormality was determined by the investigator.

Number of Participants With Clinically Significant Findings Related to Electrocardiograms (ECGs)
up to Week 18

Clinical significance was determined by the investigator.

Percent Change From Baseline in Total Immunoglobulin G (IgG), IgG1, IgG2, IgG3, and IgG4 Levels
Baseline; Week 7; Week 6 and 7 combined

The serum levels of total IgG and IgG subclasses (1-4) were determined. Percent change from Baseline was calculated as the mean value at the specified time frame (Week 7, Week 6 and 7 combined) minus the Baseline value, divided by the Baseline value x 100. A negative percent change from Baseline represents clinical improvement.

Mean Change From Baseline in Levels of Anti-thyroid-stimulating Hormone Receptor (Anti-TSHR) Antibodies at Week 7
Baseline; Week 7

The serum levels of anti-TSHR antibodies were determined. Change from Baseline was calculated as the Week 7 value minus the Baseline value. A negative change from Baseline represents clinical improvement.

Secondary Endpoints

Double-Blind Treatment Period: Area Under the Concentration-time Curve From Time 0 to 168 Hours (AUC0-168h) of RVT-1401
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Open-label Extension Period: AUC0-168h of RVT-1401
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8, Week 9, Week 12 and Week 14
Double-Blind Treatment Period: Maximum Concentration (Cmax) of RVT-1401
Pre-dose; Day 1, Day 3, Day 5, Day 8, Day 15, Day 22, Day 29, Day 36, Day 38, Day 40, Week 7, Week 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Regimen AEXPERIMENTALRVT-1401 680 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
Regimen BEXPERIMENTALRVT-1401 340 mg weekly for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
PlaceboPLACEBO_COMPARATORPlacebo for 6 weeks + optional open-label extension (RVT-1401, 340 mg every 2 weeks for 6 weeks)
RVT-1401EXPERIMENTALRVT-1401 680 milligrams (mg) weekly for two weeks followed by 340 mg weekly for four weeks, administered subcutaneously

Interventions

NameTypeDescription
RVT-1401DRUGSubcutaneous administration of RVT-1401
PlaceboDRUGSubcutaneous administration of Placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites20

Inclusion Criteria: 1. Male or female ≥ 18 years of age. 2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator. 3. QMG score ≥12 at Screening and Baseline. Other, more specific inclusion cri...

Countries:United StatesCanada
Unlock Eligibility Criteria

Frequently asked questions about RVT-1401

What is RVT-1401 used for?

RVT-1401 is an investigational small molecule being studied for the treatment of Myasthenia Gravis and Graves' Ophthalmopathy. It is being developed by Immunovant, Inc. (IMVT) and is currently in Phase 2 clinical development. RVT-1401 is not yet approved and remains under investigation.

Who makes RVT-1401?

RVT-1401 is being developed by Immunovant, Inc., a biopharmaceutical company traded under the ticker IMVT. The drug is an investigational small molecule in Phase 2 clinical development for Myasthenia Gravis and Graves' Ophthalmopathy.

What phase is RVT-1401 in?

RVT-1401 is in Phase 2 clinical development. It is an investigational small molecule being studied for Myasthenia Gravis and Graves' Ophthalmopathy. Clinical trials for both indications have been completed, and the drug is not yet approved by regulatory authorities.

What clinical trials has RVT-1401 been in?

RVT-1401 has been studied in two completed Phase 2 trials. NCT03863080 enrolled 17 patients with Myasthenia Gravis in the United States and Canada. NCT03922321 enrolled 7 patients with moderate to severe active Graves' Ophthalmopathy in Canada. Both trials were uncontrolled and not blinded.

Is RVT-1401 the same as any other drug?

RVT-1401 is the investigational name used in clinical trials for this drug. No alternative names have been reported. It is being developed by Immunovant, Inc. (IMVT) for Myasthenia Gravis and Graves' Ophthalmopathy.